- /
- Supported exchanges
- / US
- / IMVT.NASDAQ
Immunovant Inc (IMVT NASDAQ) stock market data APIs
Immunovant Inc Financial Data Overview
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Immunovant Inc (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Immunovant Inc data using free add-ons & libraries
Get Immunovant Inc Fundamental Data
Immunovant Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -538 016 000
- Earnings Per Share: -2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-11-09
- EPS/Forecast: -0.73
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Immunovant Inc News
New
Does Immunovant (IMVT) Have the Potential to Rally 30.52% as Wall Street Analysts Expect?
Shares of Immunovant, Inc. (IMVT) have gained 24.4% over the past four weeks to close the last trading session at $35.71, but there could still be a solid upside left in the stock if short-term price ...
Immunovant (IMVT) Upgraded to Buy: Here's What You Should Know
Immunovant, Inc. (IMVT) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates...
Immunovant Stock What Changed After Arthritis Trial Success
Immunovant reported past second quarter and six month results to 30 September 2026 with continued net losses alongside reduced loss per share, and paired this with a broad shelf registration and a pla...
Immunovant surges on trial results, earnings beat
Investing.com -- Immunovant Inc (NASDAQ:IMVT) shares jumped 11.7% in early trading Monday after the company reported its drug candidate IMVT-1402 met the primary endpoint in a potentially registration...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.